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Abstract
Background: Enalapril is an antihypertensive medicine that inhibits angiotensin I-converting enzyme (ACE). The
present study investigated interactions between enalapril and a fermented milk product (FMP) containing the
ACE-inhibitory peptides, Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP).
Methods: Single-dose and long-term (6-week) in vivo studies were used to investigate the effects of enalapril
and FMP on blood pressure in spontaneously hypertensive rats.
Results: Single-dose oral administration of concomitant enalapril and FMP (VPP, IPP: 3.5 mg/kg) produced a lower
antihypertensive effect than enalapril monotherapy. However, this effect was not observed in animals administered a
lower dose of FMP (VPP, IPP: 1.75 mg/kg) along with enalapril. In rats administered enalapril concomitantly with a fish
protein product (FPP) containing a different ACE inhibitory peptide (Leu-Lys-Pro-Asn-Met), significant attenuation of the
antihypertensive effect was also observed 1 and 2 h after administration, as compared to enalapril monotherapy. During a
6-week oral administration study, the enalapril monotherapy group showed significant antihypertensive effects compared
to those observed in the controls on day 28. Oral administration of enalapril and FMP, with a 1-h interval between doses,
resulted in significant antihypertensive effects on day 35, indicating a delayed onset in comparison to enalapril
monotherapy. In rats receiving enalapril monotherapy for 28 days, followed by 14 days of concomitant FMP,
significant antihypertensive effects were observed after day 35, and these did not differ significantly from the
effects observed during enalapril monotherapy.
Conclusions: The present findings suggested that long-term concomitant intake of FMP and enalapril could influence
the antihypertensive effects of this drug.
Keywords: Hypertension, Drug interaction, Fermented milk, Enalapril, Peptide, Angiotensin I-converting enzyme inhibitor,
Concomitant administration, Foods for specified health uses
Background
Foods for Specified Health Uses (FOSHU) have been ap-
proved by the Japanese Ministry of Health, Labour and
Welfare after demonstrating tangible benefits. FOSHU
may contain biologically active ingredients with a range
of activities, such as decreasing blood pressure or chol-
esterol levels. These provide prophylaxis for lifestyle-
related diseases, such as hypertension, diabetes, obesity,
osteoporosis, and cardiovascular disease [1]. At present,
many FOSHU such as tea, beverages, gum, etc. are avail-
able over-the-counter and have been widely adopted in
everyday life.
Hypertension can be treated using lifestyle measures,
such as increasing physical activity, maintaining a normal
body weight, and adopting a healthy diet. In addition, bor-
derline hypertensive subjects can ingest FOSHU containing
peptide inhibitors of angiotensin I-converting enzyme
(ACE). Several randomized trials and meta-analyses have
shown that some peptides derived from milk proteins, such
as Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), decrease sys-
tolic blood pressure [2–4]. VPP and IPP, first isolated from
milk fermented with Lactobacillus helveticus, show ACE-
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inhibitory activity and their antihypertensive effects have
been studied extensively in spontaneously hypertensive rats
(SHR) [5, 6], and in humans [7, 8]. At present, a fermented
milk product (FMP) containing these peptides is commer-
cially available in Japan (trade name, Ameel S®) and this
FOSHU is readily available to people, irrespective of
whether they are taking other antihypertensive medications.
There are few published studies on the effects of com-
bined intake of FMP and a prescribed ACE inhibitor. The
present study therefore investigated the hypotensive effects
of concomitant use of FMP and an ACE inhibitor, enalapril.
Because antihypertensive drugs are commonly adminis-
tered continuously over a long period, this study investi-
gated long-term administration of FMP and enalapril. An
initial investigation of concomitant oral administration of
enalapril and either FMP or a commercially available fish
protein product (FPP; trade name, Peptide Straight®)
containing a bioactive peptide (Leu-Lys-Pro-Asn-Met;
LKPNM) was carried out [9]. We then conducted a long-
term oral administration study to model a situation where
patients took concomitant FOSHU and enalapril, and the
other scenario where patients already taking oral antihyper-
tensive medication started to take FOSHU. SHR therefore
received daily oral concomitant enalapril and FMP for
6 weeks, or enalapril monotherapy for 28 days, followed by
concomitant FMP for a further 14 days.
Methods
Animals
This study was performed in accordance with the guide-
lines for animal experimentation of Teikyo University. Male
SHR rats were purchased from the Sankyo Laboratory
Service Corporation (Tokyo, Japan) and then under-
went a 4-week preliminary observation at 22-24 °C,
55 % humidity, with 12 h of lighting (0800–2000) and
food and water ad libitum. Thirteen-week-old rats
(body weight: 250–290 g) were used for the single ad-
ministration study and 15-week-old rats (body weight:
235–270 g) were used for the long-term administra-
tion study.
Sample preparation
One Ameel S Handy Tab® (CALPIS Co. Ltd., Tokyo,
Japan), labeled as containing 1.7 mg of VPP and IPP in
total, was crushed and dissolved in distilled water to
give a total volume of either 2.9 mL (for dosing at
3.5 mg/kg [5]) or 5.8 mL (for dosing at 1.75 mg/kg). In
the enalapril monotherapy group, 0.5 mg/mL enalapril
maleate (Wako Junyaku Inc., Tokyo, Japan) solution
was prepared using distilled water. For concomitant
enalapril and FMP administration, 1 Ameel S Handy
Tab® was crushed and added to a 1.0 mg/mL enalapril
solution to give a total volume of 2.9 mL. In the FPP
monotherapy group, one bag containing 1.9 g of
Peptide Straight® (Japan Supplement Foods Co. Ltd.,
Osaka City, Japan; 4.75 mg LKPNM) was crushed and
dissolved in distilled water to obtain a total volume of
3.5 mL. In the concomitant FPP and enalapril group,
1.9 g Peptide Straight® was crushed and added to a
0.4 mg/mL enalapril solution to give a total volume of
3.5 mL. The control group was orally administered
6 mL/kg distilled water.
Test product administration
Three types of single administration studies were con-
ducted using the following 4 groups (n = 4 rats per group):
Study 1, (I) control (distilled water), (II) enalapril (3 mg/kg)
monotherapy, (III) FMP (VPP, IPP: 3.5 mg/kg), and (IV)
concomitant enalapril (3 mg/kg) and FMP (VPP, IPP:
3.5 mg/kg); Study 2, (I) control (distilled water), (II) enala-
pril (3 mg/kg) monotherapy, (III) FMP (VPP, IPP: 1.75 mg/
kg), and (IV) concomitant enalapril (3 mg/kg) and FMP
(VPP, IPP: 1.75 mg/kg); and Study 3, (I) control (distilled
water), (II) enalapril (3 mg/kg) monotherapy; (III) FPP
(LKPNM; 10 mg/kg LKPNM [9].), and (IV) concomitant
enalapril (3 mg/kg) and FPP (LKPNM; 10 mg/kg LKPNM).
These doses of FMP and enalapril were based on the hu-
man doses of 5–10 mg enalapril daily and 3.4 mg VPP/IPP
in FMP. The test products were administered orally using a
nasogastric tube (KN-349, Natsume, Tokyo, Japan) at the
scheduled time (1000–1145). In the long-term administra-
tion study, rats received each preparation separately, with
an interval of 1 h between the first and second administra-
tion. This study was conducted using the following groups
and dosing schedules (n = 5 rats per group): (I) control (dis-
tilled water, followed by distilled water); (II) enalapril mono-
therapy (distilled water, followed by 3 mg/kg enalapril); (III)
concomitant enalapril and FMP (VPP, IPP: 3.5 mg/kg),
followed by 3 mg/kg enalapril); and (IV) delayed combin-
ation (distilled water, followed by 3 mg/kg enalapril for
28 days, switching to FMP [VPP, IPP: 3.5 mg/kg], followed
by 3 mg/kg enalapril for a further 14 days). During the
6-week study period, administration took place daily
at scheduled times (first administration: 1130–1200;
second administration: 1230–1300).
Blood pressure measurement
Systolic blood pressure was measured by the tail cuff
method using the Non-Preheating, Non-Invasive Blood
Pressure Monitor for Mice and Rats (MK-2000, Muroma-
chi Kikai, Tokyo, Japan). Blood pressure measurements
were performed 5–10 times consecutively when the rat was
at rest. During the single administration study, blood pres-
sure was measured immediately before administration and
at 1, 2, 4, and 6 h after administration. During the
long-term administration study, systolic blood pressure
was measured immediately before the start of adminis-
tration and prior to oral dosing on days 3, 7, 10, 14, 17,
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21, 24, 28, 31, 35, 38, and 42 (after day 42, no test product
was administered). This study schedule was based on a
previous report [10].
A change in the hypertensive state was calculated as a
percentage of systolic blood pressure measured immedi-
ately before the start of administration.
Statistical analyses
The mean blood pressure value was used for analysis.
Values were expressed as the mean ± standard error of
the mean (SE). After one-way analysis of variance, the




In the initial single oral dose study, blood pressure was
measured after administration of a mixture of enalapril and
FMP, to evaluate the optimal method of administration for
the subsequent long-term study. As a result, compared to
the control group, the enalapril monotherapy group
showed significant antihypertensive effects from 1 to 6 h
after administration. No significant antihypertensive effects
Fig. 1 Systolic blood pressure changes in SHR after single oral administration. Systolic blood pressure changes in SHR after single oral administration of (a)
enalapril (3.0 mg/kg, ■), FMP (VPP, IPP: 3.5 mg/kg,▲), or concomitant enalapril (3.0 mg/kg) and FMP (VPP, IPP: 3.5 mg/kg, ●); (b) enalapril (3.0 mg/kg, ■),
FMP (VPP, IPP: 1.75 mg/kg, ▲), or concomitant enalapril (3.0 mg/kg) and FMP (VPP, IPP: 1.75 mg/kg, ●); (c) enalapril (3.0 mg/kg, ■), FPP
(LKPNM: 10 mg/kg, ▲), or concomitant enalapril (3.0 mg/kg) and FPP (LKPNM: 10 mg/kg, ●). The control group (◆) received distilled water.
Values are presented as the mean ± SE (n = 4). *p < 0.05 vs enalapril monotherapy group; ✢p < 0.05; ✢✢p < 0.01 vs the control group at the
same time point (Bonferroni/Dunn, Scheffe’s F test)
Fig. 2 Systolic blood pressure changes in SHR during 6-week oral administration. Systolic blood pressure changes in SHR during 6-week oral administration
of enalapril monotherapy (■), concomitant enalapril and FMP (○), or initial enalapril monotherapy supplemented by FMP from day 29 onwards (●). The
control group (♦) received distilled water. Values are presented as the mean ± SE (n= 5). *p < 0.05 vs control group at the same time point (one-way
analysis of variance, followed by Bonferroni/Dunn or Scheffe multiple comparison tests)
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was observed in the concomitant enalapril and FMP (VPP,
IPP: 3.5 mg/kg) group 1 h after administration, although
significant antihypertensive effects were observed at 2
and 4 h (p < 0.05 each). However, significant attenu-
ation of antihypertensive effects was observed at 4 h
in the concomitant enalapril and FMP group, com-
pared with the enalapril monotherapy group (p < 0.05;
Fig. 1a). The antihypertensive effects of enalapril were
not reduced in the concomitant enalapril and FMP
(VPP, IPP: 1.75 mg/kg) group (Fig. 1b), which showed
significant blood pressure reduction from 1 to 6 h (p < 0.01
and p < 0.05) post administration. Concomitant administra-
tion of enalapril and FPP (LKPNM, 10 mg/kg) also pro-
duced significant antihypertensive effects 4 and 6 h after
administration. However, these were significantly attenu-
ated at 1 and 2 h, as compared with the enalapril mono-
therapy group (p < 0.05; Fig. 1c). This study indicated that
co-administration of FMP or FPP reduced the antihyper-
tensive effects of enalapril. Therefore, these results sug-
gested possible interactions between enalapril and ACE
inhibitory peptides from two FOSHU preparations. Because
enalapril and FMP/FPP both inhibit ACE activity, they
would be expected to have an additive antihypertensive ef-
fect. The mechanism underlying the interaction observed
in this study may therefore relate to competition for
absorption processes in the gut, resulting in reduced
enalapril-mediated antihypertensive activity. A previous
study has reported that the antihypertensive effects of
captopril decreased when this ACE inhibitor was ad-
ministered concomitantly with the Val-Tyr dipeptide,
because of their competition for peptide transporter 1
during intestinal absorption [11]. Similarly, the intes-
tinal absorption of enalapril has been reported to in-
volve peptide transporter 1 [12, 13].
Meanwhile, intestinal absorption of the highly hydro-
phobic VPP seems to occur via a paracellular pathway in-
volving tight junctions, rather than involving a peptide
transporter [14]. Furthermore, the FMP effects disap-
peared when a lower concentration was employed, per-
haps indicating a dose-dependent effect or involvement of
a saturable transporter. In addition, intestinal peptide
transporters (PEPT1 and PEPT2) exhibit high affinity for
endogenous peptides but it was not the case occasionally.
It may be probable that VPP exhibits very low affinity to
be saturated in such concentration range. Therefore, fur-
ther investigation is required to evaluate FMP pharmaco-
kinetics and to elucidate the mechanism of the observed
interaction with enalapril.
Long-term administration study
The present study found no significant differences in the
antihypertensive effects of a single oral administration of
enalapril monotherapy and oral enalapril followed by FMP
1 h later (data not shown). For this reason, we maintained a
1-h interval during dosing in the long-term study. As the
result, compared to the control group, the enalapril mono-
therapy group showed significant antihypertensive effects
on days 28, 35, 38, and 42 (p < 0.05 for all days, Fig. 2).
Although administration of enalapril and FMP with an
interval of 1 h between oral doses resulted in significant an-
tihypertensive effects (p < 0.05 on day 35 for the compari-
son with control animals), a delayed onset was observed in
comparison to that observed with enalapril monotherapy.
Despite selecting this administration method, it became
clear that long-term administration of enalapril and FMP
produced a lower antihypertensive effect than did enalapril
monotherapy. Although the mechanism underlying this ef-
fect is unknown, one possible explanation is an interaction
at ACE catalytic sites in vivo. Although the precise mecha-
nisms responsible for the in vivo antihypertensive effects of
FMP, or the IPP/VPP tripeptides, have not been elucidated
clearly, they have been suggested to involve ACE inhibition
[5], or vasodilator production [15]. IPP and VPP may also
target the aorta, where they interact with ACE catalytic
sites, inhibiting ACE activity [16–18].
When enalapril monotherapy was supplemented by
FMP, significant antihypertensive effects were observed
on days 35 and 42 (both p < 0.05) in the delayed combin-
ation group. Moreover, these effects were not signifi-
cantly different from those observed during enalapril
monotherapy (Fig. 2). This suggested that FMP adminis-
tration had no effect on ongoing enalapril treatment.
This may relate to the finding by many studies that FMP
(or VPP/IPP) only exert their effects in subjects with
clinically established hypertension [7, 19–23].
Many previous reports have shown that the long-term in-
take of FMP, or IPP and VPP tripeptides, effectively lowers
blood pressure in SHR [10, 24] and humans [7, 8, 19–22,
25–27]. However, this is the first report of a potential inter-
action between an ACE inhibitor and a FOSHU product
containing ACE inhibitory peptides in SHR with long-term
administration.
Conclusions
The present findings suggested that long-term concomi-
tant intake of FMP and enalapril could influence the an-
tihypertensive effects of this drug. Therefore, they may
be beneficial to people who have health concerns about
taking ACE inhibitors over extended periods of time.
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